Pamela Htay-Sha
Internal Medicine · Flushing, NYNPI 1861500837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 296 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$1K
- Actelion Pharmaceuticals US, Inc.$1K
- Mallinckrodt Hospital Products Inc.$647
- GSK$475
- Insmed, Inc.$431
- plus $2K from 25 others
What the payments were for
- Food & beverage$7,09496%
- Education$2694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 43 | $1,285 |
| Boehringer Ingelheim | 45 | $1,123 |
| Actelion Pharmaceuticals US, Inc. | 38 | $1,034 |
| Mallinckrodt Hospital Products Inc. | 16 | $647 |
| GSK | 21 | $475 |
| Insmed, Inc. | 19 | $431 |
| Baxter Healthcare | 12 | $237 |
| AbbVie | 11 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $206 |
| Electromed, Inc. | 11 | $167 |
| Mallinckrodt Enterprises LLC | 5 | $158 |
| Mylan Specialty L.p. | 8 | $156 |
| Novo Nordisk | 8 | $150 |
| Verona Pharma, Inc. | 5 | $147 |
| Lilly USA, LLC | 6 | $131 |
| Circassia Inc. | 6 | $99 |
| AstraZeneca | 5 | $91 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Merck | 3 | $73 |
| Sanofi | 3 | $71 |
| Bayer | 3 | $69 |
| Optinose US, Inc. | 3 | $59 |
| Viatris Specialty LLC | 2 | $54 |
| Amgen | 2 | $41 |
| Advanced Respiratory, Inc | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| 3b Medical, Inc. | 1 | $22 |
| Melinta Therapeutics, LLC | 1 | $21 |
| United Therapeutics Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$125
How this compares
$7,363 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 17 | $583 |
| Losartan Potassium | 31 | $474 |
| Famotidine | 31 | $263 |
| Atorvastatin Calcium | 22 | $224 |
| Raloxifene Hcl | 14 | $142 |
| Amlodipine Besylate | 13 | $102 |
| Metformin Hcl | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Flushing
- Weining LiangFlushing$133K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.